Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
Accepting patients
QUINTESSENTIAL-2
A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Exposed Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3